News and Comments

Dendreon’s Debate

  Thursday, September 15, 2011

For temporary negative circumstances that do not weigh against an FDA declining approval of a new drug, Dendreon’s (DNDN) stock plummeted as much as it would have if the FDA had denied it a drug approval. It was an irrational sell-off, kind of investors’ anger or vengeance against Dendreon, or someone in it. Since then, a debate started over Dendreon’s whereabouts, including its therapeutic vaccine Provenge’s efficacy and life-extending possibilities. The debate never stopped. Its temperature continued to rise, causing serious investors’ malaise and a subsequent stock malaise. The endless debate has affianced many people, including science writers, biotechnology analysts, critics, daily traders, biotech fans and both positive and negative investors. Getting confused rather than informed, a number of Prohost followers asked us to engage in the debate, or at least give an opinion over what this or that angry fellow might be suggesting. More...

Monster Blockbuster Anti-Cholesterol Drugs In Biotechs’ Pipelines

  Wednesday, August 31, 2011

The new biological science is evolving at the speed of light. As a matter of fact, the bright penetrating light of the genomic revolution is effectively reaching the dark corners where the utmost reality remained hidden since millions of years. The new light enabled the insight to match the sight in divulging the buried secrets of body at the molecular level. With the most advanced tools ever created by human minds, scientists have reached a stage where they can spend much less effort in solving much more puzzles on the road towards solving the problems of diseases at their root-origin. The successful are those researchers who keep their eyes open and their minds prepared. More...

Seattle Genetics: A powerful Approach For resistant Cancers Hits The Market

  Tuesday, August 23, 2011

We heard them all. We heard all they said, we mean the pessimist and the optimist following the approval of Seattle Genetics’ drug Adcentris™ (brentuximab vedotin) for Hodgkin lymphoma and for systemic anaplastic large cell lymphoma (ALCL). More...

Seattle Genetics: Adcentris Approved For Two Cancers

  Monday, August 22, 2011

Congratulations. A great technology, the antibody-drug conjugate (ADC) technology, which is perfected by the two biotech firms, Seattle Genetics (SGEN) and ImmunoGen (IMGN) has yielded the first approved drug. Yes, the FDA has granted accelerated approval of Adcentris™ (brentuximab vedotin) developed by Seattle Genetics (SGEN) for two indications:  More...

Array (ARRY): It is Difficult To have 14 Devils in Phase III trials

  Tuesday, August 16, 2011

One of the currently intriguing evaluations of a biotech firm is that of Array Pharmaceuticals (ARRY). Its stock has been incapable of luring investors regardless of how large is the number of its cancer products, how encouraging is the news about clinical trial results, or how generous are the upfront and promised milestone payments and royalties by the collaborating pharmaceutical companies. Array is a biotech firm that created an extraordinarily effective small molecule dug discovery and design technologies. Its technologies are state-of-the-art, built over advanced biochemistry and molecular biology. They include, high throughput screening, virtual screening, protein x-ray crystallography, structural databases and computational modeling – all assembled around a chemoinformatic databases and a library that has all sorts of molecules to pick from. The selection of molecules is made possible through its wide electronic laboratory notebook that enables scientists to generate novel predictive databases suitable for designing novel drugs out of existing molecules This drug discovery capability, which was seen by many as the most defining criterion in Array’s value, does not seem to included by the  evaluators of biotech firms. More...

Gilead, Dendreon, Seattle Genetics And Great News For CLL Patients. Who Confused Investors?

  Friday, August 12, 2011

It was crazy. During the market’s dive, Gilead’s (GILD) stock was oversold. The stock experienced a selloff after having been snubbed for years never mind it has contributed to turning a killer virus into a tamed manageable disease, or that its revenues and incomes have exceeded Wall Street exaggerated expectations.      More...

DENDREON: Are Great Expectations Gone with The Wind?

  Wednesday, August 10, 2011

But first, let us remember what we wrote in yesterday’s article related to the market’s situation. We read:  “The question is, when would big funds and institutions, sitting on billions of dollars decide that time has come to buy at the price of sand what’s much more important than gold? When would they decide to upgrade what should be upgraded and downgrade what deserves a downgrade in case any stock remained overvalued? Is this not what puts the market back on its tracks, so it could resume its function? Are there any stocks that analysts feel that they might have bottomed during the stocks’ slaughtering?” More...

ARIAD (ARIA): Announcement

  Tuesday, August 02, 2011

At this stage, we are more interested in Ariad’s (ARIA) product pipeline than in the financial results of an era where the firm will soon move from a development-stage to a revenue-generating biotech company. Our logic could be the same as that, which led Harvey J. Berger, M.D., chairman and chief executive officer of the firm to begin his financial results’ announcement by writing about the outstanding progress the firm has made towards advancing its pipeline of cancer-drug candidates. The man wrote about the firm’s expectations about the near-term drivers of shareholder value. He wrote about interim data that will be presented later this year on ponatinib trial. More important and impacting is that Merck, the firm’s partner on ridaforolimus has already filed for regulatory approval of the cancer drug with the European Medicines Agency in the European Union, and the firm’s expectation that Merck will submit a new drug application in the U.S. shortly. Another drug, AP26113, will also begin clinical development this quarter. More...

Gilead Sciences: Providing a shop full of options for individual HIV victims’ needs.

  Tuesday, August 02, 2011

Gilead Sciences (GILD): Fingers of traders on the sell button as of a routine practice has produced an initial decline in GILD price after refreshing financial results. The firm has exceeded analysts’ exaggerated expectations. Nobody was stunned about the stock’s initial decline, as everybody has become accustomed to the rule of thumb – sell on good news and obviously on bad news, i.e., sell, sell, sell; that’s all. The initial selling was initiated before and even after the announcement of Gilead’s second quarter financial results. More...

Sangamo: Aiming High

  Tuesday, July 26, 2011

In early March 2011, we gave a brief history of HIV treatments. The article has also referred to recent studies demonstrating that early treatment with highly active antiretroviral therapy (HAART) further improves survival of asymptomatic patients with higher CD4+ T cell counts. Instead of fading away as many studies do, these studies were accompanied with parallel studies demonstrating that the prophylactic use of HAART succeeded in shielding exposed individuals from contracting HIV. These studies, no doubt, were favorable to Gilead Sciences (GILD), as demonstrated in the stock’s recent performance. What makes this news important is the fact that sustained treatment with these drugs for to avert the reactivation of the virus and the progression of AIDS subjects the patients to dangerous adverse effects and the drugs to the risk of viral resistance. More...


Recent News_and_Comments


Archive


Tags